Bristol, ZymoGenetics Forge Interferon Deal

Bristol-Myers Squibb said it would pay tiny biotechnology company ZymoGenetics Inc $105 million to license, develop and sell its experimental new form of interferon to treat hepatitis C.
TradingMarkets